{
  "id": "cluster_9_doc1",
  "content": "BlueShield Health recently updated their coverage policy (CRS-229M) for proton therapy in cases of advanced chordoma. The update reflects findings from the LUMINA-4 clinical trial showing improved outcomes for patients under 50. Dr. Elara Voss at Mesa Ridge Proton Center reported a 38% increase in prior authorization requests since January 2024. New documentation requirements mandate genetic marker testing for all patients seeking this treatment.",
  "metadata": {
    "format": "policy_document"
  }
}